You might expect Eli Lilly (NYSE: LLY) to perform as big pharma companies often do: offering progressive earnings gains that translate into a steady increase for the stock over the long term. But in recent times, Lilly hasn't exactly behaved like a slow and steady healthcare player, and instead has taken the path of a fast-moving growth stock.

Lilly has jumped about 230% over three years and more than 75% over the past year. The driver of these gains is excitement about one product portfolio in particular: weight loss drugs. The company sells two now -- Mounjaro and Zepbound -- and has more candidates in late-stage clinical trials. Mounjaro and Zepbound together are bringing in billion-dollar revenue, and demand is soaring.

In recent earnings reports, this has resulted in double-digit revenue growth for the company. And investors are eager to hear the latest from the pharma giant when it reports quarterly earnings on Aug. 8. Should you get in on this high-flying stock before then? Let's find out.

Continue reading

Source Fool.com